Pattern Bioscience
Pattern Bioscience is an in vitro diagnostics company (Austin, Texas) developing a rapid, culture-free clinical microbiology platform based on single-cell analysis and machine learning to deliver pathogen identification and phenotypic antibiotic susceptibility results in hours. The company focuses on direct-from-specimen phenotypic ID/AST, instrument and consumable development, clinical validation, and regulatory clearance for tests initially targeting severe pneumonia and bacteremia.
Industries
Nr. of Employees
medium (51-250)
Patents
Compositions and methods for cellular phenotype assessment of a sample using confined volume arrays
US-12595505-B2
View DetailsMicrofluidic chips including a gutter to facilitate loading thereof and related methods
US-12551894-B2
View DetailsMicrofluidic chips including a gutter having a trough and a ridge to facilitate loading thereof and related methods
US-12415182-B2
View DetailsApparatuses for contactless loading and imaging of microfluidic chips and related methods
US-12128415-B2
View Details
Compositions and methods for cellular phenotype assessment of a sample using confined volume arrays
US-12595505-B2
View DetailsMicrofluidic chips including a gutter to facilitate loading thereof and related methods
US-12551894-B2
View DetailsMicrofluidic chips including a gutter having a trough and a ridge to facilitate loading thereof and related methods
US-12415182-B2
View DetailsApparatuses for contactless loading and imaging of microfluidic chips and related methods
US-12128415-B2
View DetailsProducts
Single-cell analysis diagnostic platform
A culture-free diagnostic platform that isolates single microbial cells in digital reactors and uses machine learning to provide pathogen identification and phenotypic antibiotic susceptibility results in hours.
Pneumonia direct-from-specimen test (in development)
A direct-from-specimen phenotypic ID/AST panel under development to provide rapid diagnostics and antibiotic susceptibility guidance for hospitalized patients with pneumonia.
Pattern Bioscience rapid phenotypic test platform
A unique rapid phenotypic test platform based on single-cell analysis of microorganisms combined with machine learning, generating clinically actionable data identifying the causal pathogen and profiling its antibiotic susceptibility in hours.
Pneumonia Action Panel
A test using Pattern's Digital Culture technology to provide fast and comprehensive diagnosis for patients hospitalized with severe pneumonia, combining machine learning and single cell analysis for rapid pathogen identification and phenotypic antibiotic susceptibility testing.
Pneumonia ID/AST Panel
Designed to identify pathogens directly from clinical samples and provide same-day phenotypic antimicrobial susceptibility profiles for over 98% of organisms typically detected in hospitalized pneumonia patients, bypassing time-consuming culture steps.
Single-Cell Microbiology platform
A rapid diagnostic technology platform that merges single-cell analysis with advanced data science to generate actionable ID/AST data within hours, bypassing bacterial growth by isolating and analyzing individual cells in picovolume-scale droplets.
Single-cell analysis diagnostic platform
A culture-free diagnostic platform that isolates single microbial cells in digital reactors and uses machine learning to provide pathogen identification and phenotypic antibiotic susceptibility results in hours.
Pneumonia direct-from-specimen test (in development)
A direct-from-specimen phenotypic ID/AST panel under development to provide rapid diagnostics and antibiotic susceptibility guidance for hospitalized patients with pneumonia.
Pattern Bioscience rapid phenotypic test platform
A unique rapid phenotypic test platform based on single-cell analysis of microorganisms combined with machine learning, generating clinically actionable data identifying the causal pathogen and profiling its antibiotic susceptibility in hours.
Pneumonia Action Panel
A test using Pattern's Digital Culture technology to provide fast and comprehensive diagnosis for patients hospitalized with severe pneumonia, combining machine learning and single cell analysis for rapid pathogen identification and phenotypic antibiotic susceptibility testing.
Pneumonia ID/AST Panel
Designed to identify pathogens directly from clinical samples and provide same-day phenotypic antimicrobial susceptibility profiles for over 98% of organisms typically detected in hospitalized pneumonia patients, bypassing time-consuming culture steps.
Single-Cell Microbiology platform
A rapid diagnostic technology platform that merges single-cell analysis with advanced data science to generate actionable ID/AST data within hours, bypassing bacterial growth by isolating and analyzing individual cells in picovolume-scale droplets.
Expertise Areas
- Clinical microbiology and phenotypic antimicrobial susceptibility testing
- Single-cell microbiology and microfluidics
- Machine learning applied to diagnostic data
- Instrumentation and hardware development for diagnostics
Key Technologies
- Single-cell analysis
- Digital cell reactors (digital culture approach)
- Phenotypic antimicrobial susceptibility testing (phenotypic AST)
- Droplet microfluidics
News & Updates
Completed a $28.7 million Series C financing to accelerate development, clinical validation, and regulatory submission of a rapid infectious disease diagnostic platform.
Raised $9M to accelerate development and clinical validation of the single-cell rapid ID/AST technology.
Received $6.8M CARB-X award plus $6.4M Series B funding to advance Digital Culture technology development.
Received Breakthrough Device designation from the U.S. Food and Drug Administration for the Pneumonia Action Panel (direct-from-specimen phenotypic ID/AST).
Recognized with a disruptive technology award in 2023.
Named a finalist in the AMR Diagnostics Challenge and awarded funding to further develop rapid ID/AST technology.
Completed a $28.7 million Series C financing to accelerate development, clinical validation, and regulatory submission of a rapid infectious disease diagnostic platform.
Raised $9M to accelerate development and clinical validation of the single-cell rapid ID/AST technology.
Received $6.8M CARB-X award plus $6.4M Series B funding to advance Digital Culture technology development.
Received Breakthrough Device designation from the U.S. Food and Drug Administration for the Pneumonia Action Panel (direct-from-specimen phenotypic ID/AST).
Recognized with a disruptive technology award in 2023.
Named a finalist in the AMR Diagnostics Challenge and awarded funding to further develop rapid ID/AST technology.